文献速递前列腺癌

局部前列腺癌主动监测可适患者的治疗开发:FDA肿瘤卓越中心公开研讨会

Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop.
PubMed 文献 · J Urol · 2019-09-10

本文总结美国FDA公开研讨会,讨论针对局部前列腺癌开发疗法的试验设计与终点选择难题。由于证明总生存或转移无生存获益需大型长期试验且缺乏公认替代终点,药物与器械开发受限。会议探讨了延迟放疗或前列腺切除所致并发症、Gleason分级组升级等新型终点,并搭建多方参与平台。

要点

  • 局部前列腺癌治疗开发受限于大型长期试验和缺乏公认替代终点。
  • 主动监测在低危和部分中危患者中广泛使用,影像与基因组学进步影响治疗范式。
  • 研讨会探讨延迟放疗或前列腺切除并发症、Gleason分级组升级等新型终点。

核心结论

  • 研讨会为推进局部前列腺癌有效治疗开发提供了多方参与的开放论坛。

研究设计与样本

  • 美国FDA公开研讨会,总结讨论内容,聚焦试验设计与终点。

主要发现

  • 证明总生存或转移无生存获益需大型试验和长期时间线,且缺乏公认替代终点。
  • 局部前列腺癌治疗范式演变包括低危和部分中危患者广泛采用主动监测,以及影像和基因组学进展。
  • 与会者讨论了延迟放疗或前列腺切除所致并发症、Gleason分级组升级等新型终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The following is a summary of discussion at a United States FDA (Food and Drug Administration) public workshop reviewing potential trial designs and end points to develop therapies to treat localized prostate cancer. MATERIALS AND METHODS: The workshop focused on the challenge that drug and device development to treat localized prostate cancer has been limited by the large trial sizes and lengthy timelines required to demonstrate an improvement in overall or metastasis-free survival and by the lack of agreed on alternative end points. Additionally, evolving treatment paradigms in the management of localized prostate cancer include the widespread use of active surveillance of patients with low and some intermediate risk prostate cancer, and the availability of advances in imaging and genomics. RESULTS: The workshop addressed issues related to trial design in this setting. Attendees discussed several potential novel end points such as a delay of morbidity due to radiation or prostatectomy and pathological end points such as Gleason Grade Group upgrade. CONCLUSIONS: The workshop provided an open forum for multiple stakeholder engagement to advance the development of effective treatment options for men with localized prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Weinstock C, Suzman D, Kluetz P, et al. Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop. J Urol. 2019. PMID: 31502940. doi:10.1097/JU.0000000000000532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。